At a glance
- Originator Takeda
- Class Cytostatic antibiotics
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Jun 2002 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 12 Jun 2000 No-Development-Reported for Cancer in Japan (Unknown route)
- 21 Feb 1995 Preclinical development for Cancer in Japan (Unknown route)